The global caspofungin market is anticipated to grow at a CAGR of around 5% during the forecast period. The caspofungin is used to treatinvasive candidiasis, invasive aspergillosis, and suspected fungal infections. Caspofungin has a significant application in patients that cannot use or do not respond to other antifungal medications such as amphotericin B, itraconazole. Additionally, caspofungin can also be used with the combination of other antifungal medicines such as voriconazole for more effective results, which is anticipated to significantly increase the growth of the caspofungin market.

Factor such as the availability of caspofungin in the generic form will increase its penetration in the developing economies at affordable price which, in turn, will drive the growth of the caspofungin market. Besides, the low awareness regarding the various internal bacterial and fungal infections in the developing economies will hamper the growth of the caspofungin market during the forecast period.

Segmental Outlook 

The caspofungin market is segmented on the basis of the infection type and dosage form. Based on the infection type, the market is sub-segmented into candidiasis and thrush. Further based on the dosage forms, the market is sub-segmented into powders, ointments, and drugs.

Global Caspofungin Market Share by Dosage Forms, 2019 (%)

Ointments to Contribute a Prominent Share

Ointments segment is anticipated to hold a significant share in the caspofungin market owing to increasing use in the bacterial infections across the globe. An ointment is an easy form of application of drugs in the outside body infected areas. The caspofungin in the form of ointment is chemically more stable than other dosage form which will increase its adoption rate in the caspofungin market. Additionally, the ointment is the most preferred dosage form in patients that have difficulty in taking the drugs as parenteral and oral routes. Moreover, the ointment dosage form is preferred mostly as it prevents any passage through the liver and only the infected part is exposed to the drug.

Regional Outlooks

The global caspofungin market is further segmented based on geography into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to hold the largest market share in the caspofungin during the forecast period. The growth of the region is owing to the increasing incidence of disease related to change in lifestyle and an increase in stress levels such as vaginal, vulvovaginal, and fungemia candidiasis. Additionally, the geriatric population of the region that is experiencing increased incidences of Candidemia and invasive aspergillosis will also fuel the growth of the caspofungin market across the region. According to the Centers for Disease Control and Prevention (CDC) report, in the population aged over 60, Candida was the fourth most common cause of bloodstream infection.

Global Caspofungin Market Growth, by Region 2020-2026

Asia-Pacific will Augment with the Fastest Growth Rate in the Caspofungin Market

Asia-Pacific is anticipated to exhibit the fastest growth rate in the caspofungin market owing to the increasing cases of fungal infection cases across the region. Additionally, the increment in the aged population across the region that is at an increased risk of developing fungal diseases will drive the caspofungin market significance across the region. As per the World Health Organization, China and Japan have the highest aged population in the Asia-Pacific region. 

Market Players Outlook

Some of the key players of the Caspofungin market include Athenex Inc., Fresenius SE & Co. KGaA, Merck & Co. Inc., Sun Pharmaceutical Industries Ltd., New Xellia Group A/S, Centrient Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Pfizer Inc., and others. The market players are considerably contributing to the market growth by adopting various strategies including new product launch, merger, and acquisition, collaborations to stay competitive in the market.

Recent Activities

• In May 2020, Fresenius Kabi announced the immediate availability in the US of Micafungin for Injection. Fresenius Kabi’s Micafungin for Injection is available in 50 mg and 100 mg strengths in a 10 mL vial.
• In August 2018, Centrient Pharmaceutical sexpanded its drug product portfolio with the launch of its first anti-fungal finished dosage formulation.
• In April 2017, Mda Inc. launched Caspofungin Acetate for Injection. The product is in two forms of packaging including 50 mg/vial and 70 mg/vial and was available at wholesalers.
• In October 2017, Mylan NV announced the launch of Caspofungin Acetate for Injection in the US. It was one of the first generic versions of Merck's Cancidas. Caspofungin Acetate for Injection is an echinocandin antifungal and is indicated to be used in adults and pediatric patients that are older than 3 months.

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global caspofungin market. Based on the availability of data, information related to products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.